Loading organizations...
Splink is an open-source Python package for probabilistic record linkage, enabling deduplication and linking of diverse datasets without unique identifiers. It employs advanced statistical methods to infer relationships between records. This technology prioritizes speed, accuracy, and scalability, integrating with multiple SQL backends for efficient large data processing.
The project originated within the Ministry of Justice (MoJ) Analytical Services, developed to address complex data linkage challenges in government operations. It emerged from the critical need for precise and scalable data integration, driving the creation of a robust solution for public sector analysis.
Splink is primarily utilized by data professionals, including scientists and analysts, who require dependable methods for cleaning and merging disparate information. Its vision centers on democratizing sophisticated record linkage capabilities through an accessible open-source framework, aiming to enhance data integrity and facilitate deeper insights.
Splink has raised $9.0M across 1 funding round.
Splink has raised $9.0M in total across 1 funding round.
Splink is a Tokyo-based technology company founded in 2017 that develops medical AI solutions focused on geriatric care, particularly addressing cognitive decline and aging-related diseases.[1] It offers tools like the "CQ test®," a self-check cognitive function measurement platform certified by Kanagawa Prefecture's "ME-BYO BRAND" in March 2025, enabling early detection and diagnostic support for conditions such as Alzheimer's and cognitive disorders to improve healthcare outcomes.[1] Serving healthcare providers and patients in Japan, Splink tackles challenges in diagnosing and treating cognitive impairments through AI-driven technology, having raised $9.81M and holding 4 patents in areas like Alzheimer's disease and cognitive disorders; it remains in the incubator/accelerator stage with recent Mosaic Score declines signaling potential market pressures.[1]
Splink was founded in 2017 in Tokyo, Japan, with headquarters at 1-14-14 WAW Akasaka, Minato-ku.[1] Led by Representative Director Yuki Aoyama, the company emerged to address gaps in geriatric care amid Japan's aging population, developing AI for early detection of cognitive issues like those tied to Alzheimer's.[1] Key early traction includes filing 4 patents on topics such as Alzheimer's disease, chess engines (potentially for cognitive assessment), and cognitive disorders, alongside product advancements like the CQ test® gaining official certification in 2025, marking a pivotal validation of its technology.[1]
Splink rides the global surge in AI for healthcare, specifically the geriatric care wave driven by aging populations—Japan's demographics amplify this, with cognitive disorders like Alzheimer's affecting millions.[1] Timing aligns with rising demand for early-detection tools amid labor shortages in elder care and post-pandemic health tech investments; market forces like government-backed certifications (e.g., ME-BYO BRAND) and AI infrastructure growth favor scalable diagnostics.[1] It influences Japan's brain health ecosystem by enabling healthcare practices to improve accuracy and efficiency, contributing to broader AI adoption in preventive medicine while competing in a 12,060-company AI field.[1]
Splink's path forward hinges on scaling CQ test® adoption and leveraging patents for global expansion beyond Japan, potentially partnering with international healthcare amid AI health booms. Trends like unsupervised AI models and personalized geriatric tech will shape it, though Mosaic Score drops suggest funding or market hurdles ahead.[1] Its influence could grow by pioneering cognitive AI standards, evolving from niche player to key enabler in aging societies—watch for new funding or partnerships to fuel momentum from its strong Japanese foundation.[1]
Splink has raised $9.0M in total across 1 funding round.
Splink's investors include APEX Capital.
Splink has raised $9.0M across 1 funding round. Most recently, it raised $9.0M Seed in July 2021.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Jul 1, 2021 | $9M Seed | — | Apex Capital | Announced |
